Pain relief drug trial for mast cell syndrome stalls early
NCT ID NCT05652907
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tested whether FSD201 tablets could reduce chronic pain in adults with mast cell activation syndrome. The study planned to enroll many participants but was terminated early with only 2 people. No results are available to show if the drug works or is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FSD201 (tablets)
- What this could lead to
- If it worked, this could point toward a treatment for chronic pain in people with mast cell activation syndrome.
- What could go wrong
- The trial was terminated early with only 2 participants, so no reliable conclusions can be drawn. It is unclear if FSD201 is safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAST CELL ACTIVATION DISORDER IDIOPATHIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Norman Marcus Pain Institute
New York, New York, 10016, United States
-
Saint Charles Clinical Research
Weldon Spring, Missouri, 63304, United States
-
Toronto Rehabilitation Institute
Toronto, Ontario, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.